Transplanting gut microbes from healthy rats into a rat model of PAH led to a reduction in disease severity, suggesting a ...

The FDA has endorsed plans for a Phase 2b clinical trial that will test CS1, Cereno Scientific's experimental treatment for ...

Yutrepia's maker, Liquidia, has scheduled a first commercial shipment of the PH therapy to be available at specialty ...

Yutrepia is an inhaled dry powder formulation of treprostinil approved in the U.S. to improve exercise capacity in PAH and PH ...

The FDA has approved Yutrepia, an inhaled treprostinil formulation, for the treatment of PAH and PH-ILD, two forms of ...

Pulmonary hypertension (PH) is a rare, life-threatening disease that affects the pulmonary arteries, the lungs, and the heart. Patients who suffer from the disease have narrow and obstructed pulmonary ...

Low-dose metformin, a medication for type 2 diabetes, delivered to the pulmonary arteries using lipid-based nanocapsules, safely eased signs of pulmonary arterial hypertension (PAH) in rats, a study ...

Six out of 10 people with pulmonary arterial hypertension who were followed for 10 years in an extension study are still ...

This is James Ramsey’s story: My name is James Ramsey. I decided to rejoin my gym in 2018, and after working out, I began feeling dizzy. It lasted for two days, at which point I wasn’t feeling right, ...

Although there is no cure yet for pulmonary hypertension (PH), there are a variety of therapies available that can help manage the symptoms of the disease and maintain or improve the quality of life ...